The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Net loss | -101,594 | -130,302 | -101,744 | -108,176 |
| Depreciation | 2,281 | 2,499 | 2,415 | 1,608 |
| Noncash operating lease expense | 3,961 | 3,745 | 3,606 | 2,420 |
| Stock-based compensation | 26,430 | 28,897 | 19,079 | 14,230 |
| Accretion on marketable securities | -2,688 | -4,617 | -3,394 | - |
| Other, net | 77 | -23 | -22 | 669 |
| Accounts receivable | - | - | -2,000 | - |
| Prepaid expenses and other current assets | 1,763 | -370 | 2,225 | 2,056 |
| Right-of-use asset | - | - | - | -10,125 |
| Other long-term assets | 299 | -43 | 41 | -122 |
| Accounts payable | -825 | -1,184 | -1,705 | 1,097 |
| Accrued expenses and other liabilities | 1,104 | 1,134 | -2,029 | 7,629 |
| Operating lease liabilities | -3,032 | -2,140 | -2,439 | 1,700 |
| Deferred revenue | -62,384 | -29,969 | -31,527 | -16,860 |
| Net cash used in operating activities | -138,886 | -131,501 | -117,982 | -109,080 |
| Purchase of property and equipment | 1,048 | 754 | 1,526 | 7,692 |
| Sales and maturities of marketable securities | 224,640 | 327,768 | 353,526 | 242,595 |
| Purchases of marketable securities | 264,457 | 240,888 | 310,574 | 208,504 |
| Net cash (used in) provided by investing activities | -40,865 | 86,126 | 41,426 | 26,399 |
| Proceeds from issuance of common stock and pre-funded warrants | 212,400 | 41,723 | 80,017 | - |
| Proceeds from issuance of common stock upon exercise of stock options and purchase of shares under espp | 10,136 | 5,941 | 1,941 | 1,623 |
| Return of capital from a stockholder - related party | - | - | 689 | - |
| Payment of business combination and pipe financing transaction costs | - | - | - | 8 |
| Payment of transaction costs | 36 | - | 241 | - |
| Net cash provided by financing activities | 222,500 | 47,664 | 82,406 | 1,615 |
| Net change in cash, cash equivalents and restricted cash | 42,749 | 2,289 | 5,850 | -81,066 |
| Cash, cash equivalents and restricted cash, beginning of period | 72,097 | 69,808 | 63,958 | 145,024 |
| Cash, cash equivalents and restricted cash, end of period | 114,846 | 72,097 | 69,808 | 63,958 |
Tango Therapeutics, Inc. (TNGX)
Tango Therapeutics, Inc. (TNGX)